Production (Stage)
Allogene Therapeutics, Inc.
ALLO
$1.06
-$0.03-2.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 0.34% | 9.58% | 0.10% | -2.09% | 24.22% |
| Total Depreciation and Amortization | -4.14% | 0.81% | -11.99% | 2.50% | 2.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.58% | -47.08% | 75.42% | 41.80% | -66.74% |
| Change in Net Operating Assets | -257.38% | 159.36% | 47.00% | -196.46% | -11.40% |
| Cash from Operations | -44.23% | 16.81% | 30.62% | -13.76% | -4.08% |
| Capital Expenditure | 61.48% | 40.09% | -- | 100.00% | 95.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -88.63% | 173.04% | -201.27% | 236.99% | -67.27% |
| Cash from Investing | -88.76% | 172.29% | -201.85% | 237.11% | -67.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 85.27% | 745.80% | -99.36% | 6,343.82% | 964.52% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -- | -- |
| Cash from Financing | 143.60% | 745.80% | -99.37% | 6,482.00% | 964.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -236.63% | 120.08% | -199.83% | 472.49% | -330.90% |